PT - JOURNAL ARTICLE AU - Xue Liu AU - Ryan J. Longchamps AU - Kerri Wiggins AU - Laura M. Raffield AU - Lawrence F. Bielak AU - Wei Zhao AU - Achilleas Pitsillides AU - Thomas Blackwell AU - Xiuqing Guo AU - Nuzulul Kurniansyah AU - Bharat Thyagarajan AU - Nathan Pankratz AU - Stephen S. Rich AU - Kent D. Taylor AU - Patricia A. Peyser AU - Susan R. Heckbert AU - Sudha Seshadri AU - L Adrienne Cupples AU - Eric Boerwinkle AU - Megan L. Grove AU - Nicholas Larson AU - Jennifer A. Smith AU - Ramachandran S Vasan AU - Tamar Sofer AU - Annette L Fitzpatrick AU - Myriam Fornage AU - Jun Ding AU - Adolfo Correa AU - Gonçalo Abecasis AU - Bruce M. Psaty AU - James G. Wilson AU - Daniel Levy AU - Jerome I. Rotter AU - Joshua C. Bis AU - Claudia L Satizabal AU - Dan E. Arking AU - Chunyu Liu TI - Association of mitochondrial DNA copy number with cardiometabolic diseases in a large cross-sectional study of multiple ancestries AID - 10.1101/2020.04.20.20016337 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.20.20016337 4099 - http://medrxiv.org/content/early/2020/04/24/2020.04.20.20016337.short 4100 - http://medrxiv.org/content/early/2020/04/24/2020.04.20.20016337.full AB - The mitochondrial genome (mtDNA) is represented at variable copy number (CN) in human cells and plays essential roles in cellular metabolism. Previous studies reported inconsistent associations between mtDNA CN and cardiometabolic disease (CMD) traits. We determined the cross-sectional association of mtDNA CN measured in whole blood with several CMD traits in ∼66,100 individuals (mean age 60, 54% women, and 21% non-European ancestries). Cohort- and ancestry-specific association and meta-analysis were performed adjusting for trait-specific covariates and batch. Because white blood cell (WBC) count, a marker of subclinical inflammation, is associated with mtDNA CN level and multiple CMD traits, we further compared associations with and without adjustment for WBCs in a subset of individuals with WBCs. In meta-analysis without cell count adjustment in European ancestry (EA) participants (n=52,500), lower mtDNA CN was associated with higher odds of obesity (OR with 95% CI=1.13 (1.11, 1.16), P=3.3e-30) and hypertension (OR=1.05 (1.03, 1.08), P=4.0e-07). Further adjusting for WBCs in a subset of EA participants (N=44,100), associations became non-significant (P>0.05) for hypertension, attenuated for obesity (ORwithout cell counts=1.15 (1.12, 1.18) versus ORcell counts=1.06 (1.03, 1.08)) but strengthened for hyperlipidemia (ORwithout cell counts =1.03 (1.00, 1.06) versus ORcell counts =1.06 (1.03, 1.09)). The magnitude and directionality of most associations were consistent between participants of European and other ancestries. Understanding the role of mtDNA CN in CMD will provide insight into the pathobiology underlying metabolic diseases. Further research on modifiable factors that influence mtDNA CN may help develop therapeutic strategies for preventing and treating metabolic diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Funding support for "Building on GWAS for NHLBI-diseases: the U.S. CHARGE consortium" was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419). Sequencing was carried out at the Baylor College of Medicine Human Genome Sequencing Center and supported by the National Human Genome Research Institute grants U54 HG003273 and UM1 HG008898. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). WGS for "NHLBI TOPMed: Atherosclerosis Risk in Communities" (phs001211.v3.p2.c1) was performed at the Broad Institute for MIT and Harvard (3R01HL092577-06S1). WGS for "Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing (WGS) Project: ARIC" (phs001211.v3.p2.c1) was performed at the Baylor College of Medicine Human Genome Sequencing Center. Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1). Phenotype harmonization, data management, sample-identity QC, and general study coordination, were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed.Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). WGS for NHLBI TOPMed: CARDIA (phs001612) was performed at the Baylor Human Genome Sequencing Center (HHSN268201600033I). Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1). Phenotype harmonization, data management, sample-identity QC, and general study coordination, were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. The Coronary Artery Risk Development in Young Adults Study (CARDIA) is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C from the National Heart, Lung, and Blood Institute (NHLBI), the Intramural Research Program of the National Institute on Aging (NIA), and an intra-agency agreement between NIA and NHLBI (AG0005). as noted in dbGaP. The authors also wish to thank the staffs and participants of the CARDIA.The Cardiovascular Health Study (CHS) (phs001368.v1.p1) was supported by contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. Sequencing was supported and conducted in collaboration with Baylor University (HHSN268201600033I, 3U54HG003273-12S2, HHSN268201500015C) contracts from NHLBI.The WGS for FHS (phs000974) was performed at the Broad Institute of MIT and Harvard (3R01HL092577-06S1 and 3U54HG003067-12S2). The FHS acknowledges the support of contracts NO1-HC-25195, HHSN268201500001I and 75N92019D00031 from the National Heart, Lung and Blood Institute and grant supplement R01 HL092577-06S1 for this research. We also acknowledge the dedication of the FHS study participants without whom this research would not be possible. Dr. Vasan is supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. X.L., S.S., C.L.S, and C.L. are also supported by individual funding (R01AG059727).Support for GENOA was provided by the National Heart, Lung and Blood Institute (HL054457, HL054464, HL054481, HL119443, and HL087660) of the National Institutes of Health. Sequencing for the Genetic Epidemiology Network of Arteriopathy (GENOA) (phs001345.v1.p1) was performed by the University of Washington Northwest Genomics Center (3R01HL055673-18S1 from the National Heart, Lung, and Blood Institute (NHLBI) and at the Broad Institute of MIT and Harvard (HHSN268201500014C)). The authors also wish to thank the staff and participants of GENOA.The Jackson Heart Study (JHS) (phs000964.v1.p1) is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities (NIMHD). WGS was performed at University of Washington (HHSN268201100037C).The authors also wish to thank the staffs and participants of the JHS.Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). WGS for "NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA)" (phs001416.v1.p1) was performed at the Broad Institute of MIT and Harvard (3U54HG003067-13S1). Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1). Phenotype harmonization, data management, sample-identity QC, and general study coordination, were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1). MESA and the MESA SHARe project (phs001416.v1.p1) are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420. Also supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.HCHS_SOL of Latinos is a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I / N01-HC-65233), University of Miami (HHSN268201300004I / N01-HC-65234), Albert Einstein College of Medicine (HHSN268201300002I / N01-HC-65235), University of Illinois at Chicago – HHSN268201300003I / N01-HC-65236 Northwestern Univ), and San Diego State University (HHSN268201300005I / N01-HC-65237). The WGS of HCHS/SOL (phs001395) was performed at Baylor Human Genome Sequencing Center (HHSN268201600033I). The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements.This research has been conducted using the UK Biobank Resource under Application Number 17731.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were generated at NHLBI's TOPMed program and can be requested upon approval from TOPMed. Derived data supporting the findings of this study are available from the corresponding author C.Liu on request.